Avadel Pharmaceuticals plc
AVDL
$14.20
$0.201.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.15% | 93.21% | 159.14% | 613.22% | 2,674.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.15% | 93.21% | 159.14% | 613.22% | 2,674.33% |
| Cost of Revenue | 128.34% | 266.43% | 594.37% | 5,160.68% | 7,644.44% |
| Gross Profit | 59.53% | 82.94% | 143.06% | 536.07% | 2,551.78% |
| SG&A Expenses | 2.57% | -6.26% | 8.04% | 3.16% | 1.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.22% | 4.32% | 21.09% | 19.53% | 6.29% |
| Operating Income | 169.73% | 88.47% | 86.76% | 99.07% | 74.28% |
| Income Before Tax | 145.32% | 82.23% | 82.82% | 92.99% | 77.73% |
| Income Tax Expenses | -522.79% | -16.13% | 180.00% | -1.12% | -665.56% |
| Earnings from Continuing Operations | 169.92% | 82.01% | 82.48% | 92.76% | 78.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 169.92% | 82.01% | 82.48% | 92.76% | 78.55% |
| EBIT | 169.73% | 88.47% | 86.76% | 99.07% | 74.28% |
| EBITDA | 180.88% | 91.46% | 89.25% | 102.05% | 74.86% |
| EPS Basic | 169.47% | 82.93% | 83.67% | 93.27% | 82.76% |
| Normalized Basic EPS | 143.15% | 82.64% | 82.31% | 92.65% | 76.40% |
| EPS Diluted | 169.47% | 83.03% | 83.67% | 92.68% | 82.76% |
| Normalized Diluted EPS | 142.13% | 82.64% | 82.31% | 92.65% | 76.40% |
| Average Basic Shares Outstanding | 0.60% | 5.35% | 7.22% | 7.74% | 24.47% |
| Average Diluted Shares Outstanding | 3.05% | 5.35% | 7.22% | 7.74% | 24.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |